Fig. 4: Aldometanib lowers blood glucose in obese hyperglycaemic mice.
From: The aldolase inhibitor aldometanib mimics glucose starvation to activate lysosomal AMPK
a,b, Treatment with aldometanib for 1 week decreased blood glucose in HFD-induced obese mice. Experiments were performed as in Fig. 3b, except that mice fed with a HFD for 16 weeks were used, and mice were gavaged with aldometanib twice daily for a week. Results are shown as the mean ± s.e.m.; n = 6 mice for each treatment; P values were determined by two-way RM (blood glucose and insulin values) or one-way (AUC values) ANOVA followed by Tukey’s test, and are labelled as in Fig. 3a. c–f, The 1-week treatment of aldometanib did not change body composition and energy metabolism in HFD-induced obese mice at effective doses. Mice were treated with 2 mpk, 4 mpk (effective doses) or 10 mpk (high dose) aldometanib for 1 week, followed by determination of body weight (c); body composition (d); EE, RQ and ambulatory activity (e); and rectal (f; upper) and surface (f, lower panel) temperatures. Data are shown as the mean ± s.e.m., except e as in Fig. 3h (for analysis of covariance (ANCOVA), the normalized weight was 45.2 g); n = 9 (c, d and f) or 7 (e) mice for each treatment; P values were determined by two-way RM ANOVA, followed by Tukey’s test (c; P values are indicated as in Fig. 3a) or Sidak’s test (lower part of f), by two-way ANOVA followed by Tukey’s test (e; except ANCOVA analysis), or by one-way ANOVA followed by Dunn’s test (BAT, spleen, kidney, heart and brain of d; and upper part of f), Dunnet’s test (fat mass of f) or Tukey’s test (others). Experiments were performed three times.
